Research output per year
Research output per year
Personal profile
Research interests
We are mainly interested in DNA damage responses and how this knowledge can be used to optimize tumor treatment. The main focus of the lab is on repair of DNA double strand breaks by non-homologous end-joining and homologous recombination. We are currently mainly working on culturing tumor specimens, such as thin tumor slices, and using them for functional assays. We are developing tests to predict tumor responses in patients upon treatment with chemotherapy or radiation therapy.
Fingerprint
Dive into the research topics where Dik van Gent is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Development of an Ex Vivo Functional Assay for Prediction of Irradiation Related Toxicity in Healthy Oral Mucosa Tissue
Pachler, K. S., Lauwers, I., Verkaik, N. S., Rovituso, M., van der Wal, E., Mast, H., Jonker, B. P., Sewnaik, A., Hardillo, J. A., Keereweer, S., Monserez, D., Kremer, B., Koppes, S., van den Bosch, T. P. P., Verduijn, G. M., Petit, S., Sørensen, B. S., van Gent, D. C. & Capala, M. E., 28 Jun 2024, In: International Journal of Molecular Sciences. 25, 13, 7157.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile12 Downloads (Pure) -
Ex vivo radiation sensitivity assessment for individual head and neck cancer patients using deep learning-based automated nuclei and DNA damage foci detection
Lauwers, I., Pachler, K. S., Capala, M. E., Sijtsema, N. D., Van Gent, D. C., Rovituso, M., Hoogeman, M. S., Verduijn, G. M. & Petit, S. F., Mar 2024, In: Clinical and Translational Radiation Oncology. 45, 100735.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Citation (Scopus)12 Downloads (Pure) -
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient
Meijer, T. G., Martens, J. W. M., Prager-van der Smissen, W. J. C., Verkaik, N. S., Beaufort, C. M., van Herk, S., Robert-Finestra, T., Hoogenboezem, R. M., Ruigrok-Ritstier, K., Paul, M. W., Gribnau, J., Bindels, E. M. J., Kanaar, R., Jager, A., van Gent, D. C. & Hollestelle, A., 2 Feb 2024, In: Cancers. 16, 4, 741.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Citation (Scopus)10 Downloads (Pure) -
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients
Ladan, M. M., Meijer, T. G., Verkaik, N. S., de Monye, C., Koppert, L. B., Oomen-de Hoop, E., van Deurzen, C. H. M., Kanaar, R., Nonnekens, J., van Gent, D. C. & Jager, A., Dec 2023, In: npj Breast Cancer. 9, 1, 7 p., 80.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile21 Downloads (Pure) -
Establishing a Microfluidic Tumor Slice Culture Platform to Study Drug Response
Komar, Z. M., van Gent, D. C. & Chakrabarty, S., Mar 2023, In: Current Protocols. 3, 3, e693.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Citation (Scopus)61 Downloads (Pure)